scholarly journals Minimally Invasive Model Based Stressed Blood Volume as an Index of Fluid Responsiveness

2020 ◽  
Vol 53 (2) ◽  
pp. 16257-16262
Author(s):  
L.F Murphy ◽  
J. G Chase ◽  
S. M Davidson ◽  
R. Smith ◽  
T. Desaive
2020 ◽  
Author(s):  
Dae-Myoung Yang ◽  
David A. Palma ◽  
Keith Kwan ◽  
Alexander V. Louie ◽  
Richard Malthaner ◽  
...  

Abstract Background: Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [18F]FDG-PET and CT Perfusion (CTP).Methods: Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [18F]FDG-PET provided maximum and mean standardized uptake value (SUV) and kinetic parameters estimated using a previously developed flow-modified two-tissue compartment model while CTP measured blood flow, blood volume and vessel permeability surface product. Using recursive partitioning analysis (RPA), the imaging-based biomarkers for predicting pCR were assessed and compared to current RECIST (Response Evaluation Criteria in Solid Tumours version 1.1) and PERCIST (PET Response Criteria in Solid Tumours version 1.0) criteria.Results: RPA identified three patient groups based on tumour blood volume before SABR (BVpre-SABR) and change in SUV­max (ΔSUVmax). The highest true pCR rate of 92% was observed in the group with BVpre-SABR < 9.3 mL/100g and ΔSUVmax < -48.9% after SABR while the worst was observed in the group with BVpre-SABR ≥ 9.3 (0%). A logistic regression model based on RPA risk groups showed excellent pCR prediction (Concordance: 0.92; P=0.03). RECIST and PERCIST showed poor pCR prediction (Concordance: 0.54 and 0.58, respectively).Conclusions: In this study, we developed a predictive model based on dynamic [18F]FDG-PET and CT Perfusion imaging that was significantly better than RECIST and PERCIST criteria to predict pCR of NSCLC to SABR. This model warrants validation with larger sample size studies.Trial registration: MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355


2008 ◽  
Vol 41 ◽  
pp. S391
Author(s):  
Carole Leguy ◽  
Marielle Bosboom ◽  
Arnold Hoeks ◽  
Frans van de Vosse
Keyword(s):  

2020 ◽  
Author(s):  
Dae-Myoung Yang ◽  
David A. Palma ◽  
Keith Kwan ◽  
Alexander V. Louie ◽  
Richard Malthaner ◽  
...  

Abstract Background:Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model fortrue pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [18F]FDG-PET and CT Perfusion (CTP).Methods:Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [18F]FDG-PET provided maximum and mean standardized uptake value (SUV) and kinetic parameters estimated using a previously developed flow-modified two-tissue compartment model while CTP measured blood flow, blood volume and vessel permeability surface product. Using recursive partitioning analysis (RPA), the imaging-based biomarkers for predicting pCRwere assessedand compared to current RECIST (Response Evaluation Criteria in Solid Tumours version 1.1) and PERCIST (PET Response Criteria in Solid Tumours version 1.0) criteria.Results: RPA identified threepatient groups based on tumour blood volume before SABR (BVpre-SABR) and change in SUV­max (ΔSUVmax).The highest true pCR rate of 92%was observed in the group withBVpre-SABR< 9.3 mL/100g and ΔSUVmax< -48.9% after SABR while the worst was observed in the group with BVpre-SABR ≥ 9.3 (0%). A logistic regression model based on RPA risk groupsshowedexcellentpCRprediction(Concordance: 0.92; P=0.03). RECIST and PERCIST showed poor pCRprediction (Concordance: 0.54 and 0.58, respectively).Conclusions: In this study, we developed a predictive model based on dynamic [18F]FDG-PET and CT Perfusion imaging that was significantly better than RECIST and PERCIST criteria to predict pCR of NSCLC to SABR. This model warrants validation with larger sample size studies.Trial registration:MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355


Sign in / Sign up

Export Citation Format

Share Document